Susavion Has a Robust Pipeline of Preclinical Drug Candidates for Immunotherapy.
Multiple Therapeutic Indications
Susavion has developed a series of peptides that are effective at nanomolar concentrations. These drugs are showing early promise in enhancing the immune defense in the treatment of cancer and viral infections.
svL4 has been shown to significantly extend the life of mice with ovarian cancer and significantly extend life when administered in conjunction with low doses of radiation in a glioblastoma brain tumor mouse model. svL4 reduces the growth of melanoma tumors and dramatically lowers, regulatory T cells within tumors. sv6D is a second-generation peptide based on the parent svL4 and has significantly greater efficacy in suppression of ascites formation in a mouse model of ovarian cancer. sv6D is effective as a monotherapy and is an excellent complement to other therapies such as paclitaxel and anti-PD-1 treatments. The peptides are effective in treating melanoma, multiple myeloma, and breast and renal cancer. Topically applied svL4 is also effective in the treatment of eczema.
